Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer.

ABSTRACT:

Objective

Inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) are targeted therapeutic drugs for breast cancer treatment. The mechanism of resistance to these inhibitors requires further investigation.

Methods

We used bioinformatics to screen differentially expressed genes between cells that were susceptible and resistant to CDK4/6 inhibitors. Quantitative real-time PCR (qRT-PCR) was used to identify gene expressions in different cell lines. Cell viability, colony formation, cell cycle, and apoptosis assays were used to evaluate the effect of carboxypeptidase vitellogenic like (CPVL) on breast cancer cells under the condition of CDK4/6 inhibitors. Gene set enrichment analysis (GSEA) suggested the potential regulatory pathway of CPVL in breast cancer. Xenograft formation a

SUBMITTER: Zhu X 

PROVIDER: S-EPMC10101830 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature